Heya Pharmaceutical's New Drug Discovery Laboratory (Phase II) officially put into operation

On December 1, 2021, Fangda Pharmaceutical announced that its wholly-owned subsidiary Heya Pharmaceutical's New Drug Discovery Laboratory (Phase II) was officially put into operation. The laboratory is located in Jiechang Park, East High-tech Industrial Zone of Zhangjiang, with a total area of 1,660 square meters.10 standard pharmacochemical laboratories have been built，100 fume hoodsand supporting analytical testing laboratories. The completion and commissioning of the second phase of the project marks Heya PharmaceuticalIssuance of new drugsNowService capacity will be increased by approximately 50%.

Heya Pharmaceutical was founded in Silicon Valley in the US in 2001, and the Shanghai R&D center was put into operation in 2009. Currently, it has a R&D area of 8,200 square meters in the East High-tech Industrial Zone of Zhangjiang, Shanghai, with a total of nearly 300 employees.It is mainly engaged in chemical-oriented pharmaceutical development and pharmaceutical research and development services, especially research and development of antibiotics, hepatitis C and AIDS drugs.In the 20 years since its establishment, Heya Pharmaceutical has successively won honors such as “Shanghai Advanced Technology Service Enterprise”, “Shanghai Key Service Outsourcing Enterprise”, “Shanghai Multinational Enterprise R&D Center”, Zhangjiang Science City's 2019 “Innovation and Development Award”, and Johnson & Johnson JLABS Global New Drug R&D Service Provider. Heya Pharmaceutical has been deeply involved in pharmaceutical research and development for many years. It has successfully developed innovative drug projects for many biotechnology and pharmaceutical companies engaged in drug discovery and development activities, and has received widespread praise.

1

2

3

4

5

6

In 2020, Heya Pharmaceutical was officially acquired by Fangda Pharmaceuticals. Fangda Pharmaceutical is a comprehensive pharmaceutical research and development CRO company. It has separate bioanalysis centers, formulation product development centers, clinical operation centers, pharmacochemical centers, and pre-clinical safety assessment centers in China and North America. It provides global pharmaceutical companies with one-stop R&D outsourcing services such as medicinal chemistry, drug activity screening, pharmaceutical research, DMPK, pre-clinical safety assessment, bioanalysis, central laboratory and BE clinical research.

Fonda Pharmaceuticals

Fonda Pharmaceuticals is a full-service pharmaceutical R&D CRO company, inChinawithNorth AmericaBuilt separatelyCentre for Biological Analysis，Pharmaceutical Product Development Center，Clinical Operations Center，Medicinal Chemistry CenterwithPreclinical Safety Assessment Centre。 Provide one-stop R&D outsourcing services to pharmaceutical companies worldwide, including pharmacochemistry, drug activity screening, pharmacological research, DMPK, preclinical safety assessment, bioanalysis, central laboratory and BE clinical research.

Fonda's medicine has always been respected.”Two countries in Central America, the same quality system” Guidelines, obtained test data to support global declarations. In the 20 years of operation, Fangda Pharmaceutical has established an experienced research team and a solid quality management system, which has now been successfully passed50Many times the US FDA and more than100Site inspection of the sub-NMPA.

Fonda Pharmaceuticals